Anlotinib and irinotecan for advanced Ewing sarcoma after failure of standard therapy: A multicenter, two-cohort, single-arm, open label, phase Ib/II trial (NCT03416517).

被引：0
|
作者：
Xu, Jie
Xie, Lu
Guo, Wei
Tang, Xiaodong
Yang, Rongli
Yan, Taiqiang
Liu, Kuisheng
Gu, Jin
机构：
[1] Peking Univ, Peoples Hosp, Beijing, Peoples R China
[2] Peking Univ, Canc Hosp, Beijing, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
11012
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Update results of paclitaxel and cisplatin in combination with anlotinib as first-line regimen for patients with advanced ESCC: A multicenter, single-arm, open-label phase. clinical trial.
    Wang, Junsheng
    Wu, Tao
    Luo, Suxia
    Li, Ning
    Hong, Yonggui
    Guo, Yanzhen
    Cheng, Yufeng
    Li, Baosheng
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [32] Surufatinib plus toripalimab in patients with advanced neuroendocrine tumours and neuroendocrine carcinomas: An open-label, single-arm, multi-cohort phase II trial
    Zhang, Panpan
    Shi, Si
    Xu, Jianming
    Chen, Zhendong
    Song, Lijie
    Zhang, Xing
    Cheng, Ying
    Zhang, Yanqiao
    Ye, Feng
    Li, Zhiping
    Yin, Fei
    Ji, Dongmei
    Gao, Heli
    Li, Yi
    Chen, Wei
    Yang, Minjie
    Weng, Desheng
    Wu, Chunjiao
    Ma, Yue
    Sheng, Wang
    Zhao, Yaqin
    Yin, Xiaolei
    Shen, Weina
    Su, Weiguo
    Shi, Michael
    Fan, Songhua
    Tan, Panfeng
    Xu, Qian
    Lu, Min
    Shen, Lin
    EUROPEAN JOURNAL OF CANCER, 2024, 199
  • [33] Paclitaxel and cisplatin combined with anlotinib as first line regimen for advanced esophageal squamous cell carcinoma (ESCC): A single-arm, multicentre open-label phase II clinical trial
    Wang, J-S.
    Wu, T.
    Hong, Y-G.
    Guo, Y-Z.
    Luo, S-X.
    Li, N.
    Cheng, Y-F.
    Li, B-S.
    ANNALS OF ONCOLOGY, 2020, 31 : S910 - S911
  • [34] Bladder preservation therapy in combination with atezolizumab and radiation therapy for invasive bladder cancer (BPT-ART): An open-label, single-arm, multicenter, phase II trial
    Nagumo, Y.
    Kimura, T.
    Ishikawa, H.
    Sekino, Y.
    Maruo, K.
    Mathis, B. J.
    Takemura, M.
    Kageyama, Y.
    Ushijima, H.
    Kawai, T.
    Yamashita, H.
    Azuma, H.
    Naiki, T.
    Kobayashi, Y.
    Inokuchi, J.
    Osawa, T.
    Kita, Y.
    Tsuzuki, T.
    Hashimoto, K.
    Nishiyama, H.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1332 - S1333
  • [35] BORTEM-17: A PHASE IB/II SINGLE-ARM, CONTROL NON-RANDOMIZED, MULTICENTRE, OPEN LABEL CLINICAL TRIAL FOR RECURRENT GLIOBLASTOMA WITH UNMETHYLATED MGMT PROMOTER (NCT03643549)
    Goplen, D.
    Rahman, M. A.
    Arnesen, V. S.
    Brekke, J.
    Simonsen, A.
    Andreas, W.
    Marienhagen, K.
    Oltedal, L.
    Haasz, J.
    Miletic, H.
    Solheim, T. S.
    Brandal, P.
    Lie, S. A.
    Chekenya, M.
    NEURO-ONCOLOGY, 2021, 23 : 39 - 39
  • [36] Olaparib as salvage treatment for advanced germ cell tumors after chemotherapy failure: Results of the open-label, single-arm, IGG-02 phase II trial.
    De Giorgi, Ugo
    Schepisi, Giuseppe
    Gurioli, Giorgia
    Pisano, Carmela
    Basso, Umberto
    Lolli, Cristian
    Petracci, Elisabetta
    Casadei, Chiara
    Cecere, Sabrina Chiara
    Attademo, Laura
    Clemente, Alberto
    Zampiga, Valentina
    Galla, Valentina
    Cangini, Ilaria
    Di Napoli, Marilena
    Valmorri, Linda
    Pignata, Sandro
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [37] Anlotinib plus oral fluoropyrimidine S1 in treating patients with refractory or relapsed small cell lung cancer (SALTER TRIAL): An open-label, multicenter, single-arm, phase II trial
    Wang, W.
    Lv, D.
    Wu, X.
    Ye, J.
    Zhou, C.
    Wang, J.
    Ling, L.
    Yang, H.
    ANNALS OF ONCOLOGY, 2021, 32 : S1164 - S1164
  • [38] Gemcitabine plus sirolimus for relapsed and progressing osteosarcoma patients after standard chemotherapy: a multicenter, single-arm phase II trial of Spanish Group for Research on Sarcoma (GEIS)
    Martin-Broto, J.
    Redondo, A.
    Valverde, C.
    Vaz, M. A.
    Mora, J.
    Garcia del Muro, X.
    Gutierrez, A.
    Tous, C.
    Carnero, A.
    Marcilla, D.
    Carranza, A.
    Sancho, P.
    Martinez-Trufero, J.
    Diaz-Beveridge, R.
    Cruz, J.
    Encinas, V.
    Taron, M.
    Moura, D. S.
    Luna, P.
    Hindi, N.
    Lopez-Pousa, A.
    ANNALS OF ONCOLOGY, 2017, 28 (12) : 2994 - 2999
  • [39] A single-arm, open-label, multicenter phase II trial (CheckMate 172) of nivolumab (NIVO) safety in European patients (pts) with advanced melanoma (MEL) who have progressed after ipilimumab therapy (IPI).
    Schadendorf, Dirk
    Ascierto, Paolo Antonio
    Espinosa, Enrique
    Haanen, John B. A. G.
    Hermann, Frank
    Nathan, Paul D.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [40] EVOLVE: A Multicenter Open-Label Single-Arm Clinical and Translational Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer after PARP Inhibition Progression
    Lheureux, Stephanie
    Oaknin, Ana
    Garg, Swati
    Bruce, Jeffrey P.
    Madariaga, Ainhoa
    Dhani, Neesha C.
    Bowering, Valerie
    White, Justin
    Accardi, Sarah
    Tan, Qian
    Braunstein, Marsela
    Karakasis, Katherine
    Cirlan, Iulia
    Pedersen, Stephanie
    Li, Tiantiam
    Farinas-Madrid, Lorena
    Lee, Yeh Chen
    Liu, Zhihui
    Pugh, Trevor J.
    Oza, Amit M.
    CLINICAL CANCER RESEARCH, 2020, 26 (16) : 4206 - 4215
12345